UK markets closed
  • NIKKEI 225

    28,608.59
    -909.71 (-3.08%)
     
  • HANG SENG

    28,013.81
    -581.89 (-2.03%)
     
  • CRUDE OIL

    64.93
    +0.01 (+0.02%)
     
  • GOLD FUTURES

    1,835.20
    -2.40 (-0.13%)
     
  • DOW

    34,220.73
    -522.09 (-1.50%)
     
  • BTC-GBP

    39,626.27
    -1,555.01 (-3.78%)
     
  • CMC Crypto 200

    1,500.96
    +1,258.28 (+518.49%)
     
  • ^IXIC

    13,344.93
    -56.92 (-0.42%)
     
  • ^FTAS

    3,962.98
    -97.82 (-2.41%)
     

3 Biotech Stocks Ripe for Spring Portfolio Cleaning

Patrick Bafuma, The Motley Fool
·6-min read
3 Biotech Stocks Ripe for Spring Portfolio Cleaning
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

This April, many previous growth stocks have cooled, and the biotech sector is no exception. FibroGen (NASDAQ: FGEN), Novavax (NASDAQ: NVAX), and Editas Medicine (NASDAQ: EDIT) have all taken a beating for various reasons. It usually is not a reassuring sign to see that, right before going in front of the U.S. Food and Drug Administration (FDA) for review, a company wants to clarify prior data in regards to cardiovascular safety.